Clinical Analysis of 153 Cases of Refractory/Relapsed Diffuse Large B-cell Lymphoma / 中国实验血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To analyze the clinical features and treatment methods of refractory/relapsed diffuse large B cell lymphoma (DLBCL) patients, and to explore the curative effect and the main factors affecting prognosis.</p><p><b>METHODS</b>Clinical data of 1043 cases of DLBCL in our hospital from January 2008 to April 2016 were retrospectively analyzed, then the clinical data of 153 patients with refractory/relapsed lymphoma were selected and analyzed for determing the relationship of the related factors with therapeutic effect and prognosis. Treatment methods include chemotherapy alone and chemotherapy combined with radio-therapy, the first line regimen was CHOP or R-CHOP program, the salvage regimens are ICE, Hyper CVAD or EPOCH, etc. The median age of these 153 patients was 50 years old, the ratio of male and female was 1.591.</p><p><b>RESULTS</b>4 cases were not treated in 153 patients, 6 cases (4.03%) of 149 patients have been treated and achieved complete remission(CR), 18 cases (12.08%) achieved partial remission(PR), and the total response rate was 16.1%. Single factor analysis showed that the patients' serum LDH values, IPI score, bulky, extra-node involvement, bone marrow infiltration and the salvage regimen all could influence the survival rate, with statistically significantce (P<0.05).</p><p><b>CONCLUSION</b>Refractory/relapsed DLBCL mainly occurs in the middle-aged and male, the serum LDH value, IPI score, bulky and scope of lesions are mainly factors influencing the prognosis of refractory/relapsed DLBCL patients.</p>